Nona Biosciences Launches AI Platform Hu-mAtrIx™ For Drug Development
Cambridge, Massachusetts, USA, 7th March, 2025 – Nona Biosciences has launched Hu-mAtrIx™, an AI-enabled solution that integrates with its proprietary technology Harbour Mice® to facilitate accelerated antibody discovery for treatment and cure of neurodegenerative and metabolic diseases.
As the impact of this platform extends to shortening discovery periods, it also positively affects the success rate of the antibody drug development process.
Hu-mAtRix™ searches through vast databases of human antibody sequences to pinpoint candidates that take specificity and binding affinity to the target to the optimal level. It also predicts critical antibody attributes, such as stability, manufacturability, and immunogenicity, significantly lowering the chances of development risks during early-stage discovery phases.
Enriched proprietary AI model integrates with Nona Biosciences’ HCAb Plus™ platform and enables harnessing the full potential of HCAb Harbour Mice®, a fully human heavy-chain only transgenic mouse platform, for faster, more precise, and efficient identification of rare but highly specific antibodies.
“We are thrilled to roll out Hu-mAtrIx™ as an enhancement tool for our current antibody discovery offering and claim that this new platform will serve as an assistant in achieving better results,”
Commented Dr Jingsong Wang, the Chairman of Nona Biosciences.
“The combination of our proprietary Harbour Mice® technologies alongside AI is combatting drug discovery primary issues; time to market, likelihood of successful candidates, and offering our partners with directed therapeutic solutions.”
Global biotechnology companies Nona Biosciences focuses on new technology development and the provision of integrated idea to IND (Innovation: from “I to I™”) solutions from the target validation and the antibody discovery till the preclinical study.
They offer antigen preparation, animal immunization, antibody screening, and lead generation and engineering. Further, they provide developability assessment and pharmacological evaluation services. The company works on fostering international innovations of novel paradigm shifting drugs.
Read Latest Stories:
$200 Billion Potential: Fireblocks-AWS Tokenization Deployment Blueprint
Salesforce’s New AI Agentforce Set to Disrupt Global Labor Market
